SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

4D Molecular Therapeutics Q3 2026 net loss widens 37% to $78.06 million

4D Molecular Therapeutics Q3 2026 net loss widens 37% to $78.06 million 4D Molecular Therapeutic

FDMT

Related stories